Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patientsReport as inadecuate

Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients - Download this document for free, or read online. Document in PDF available to download.

Critical Care

, 12:R69

First Online: 20 May 2008Received: 26 September 2007Revised: 15 February 2008Accepted: 20 May 2008


IntroductionPreventing carriage of potentially pathogenic micro-organisms from the aerodigestive tract is an infection control strategy used to reduce the occurrence of ventilator-associated pneumonia in intensive care units. However, antibiotic use in selective decontamination protocols is controversial. The purpose of this study was to investigate the effect of oral administration of a probiotic, namely Lactobacillus, on gastric and respiratory tract colonization-infection with Pseudomonas aeruginosa strains. Our hypothesis was that an indigenous flora should exhibit a protective effect against secondary colonization.

MethodsWe conducted a prospective, randomized, double-blind, placebo-controlled pilot study between March 2003 and October 2004 in a 17-bed intensive care unit of a teaching hospital in Clermont-Ferrand, France. Consecutive patients with a unit stay of longer than 48 hours were included, 106 in the placebo group and 102 in the probiotic group. Through a nasogastric feeding tube, patients received either 10 colony-forming units unity forming colony of Lactobacillus casei rhamnosus or placebo twice daily, from the third day after admission to discharge. Digestive tract carriage of P. aeruginosa was monitored by cultures of gastric aspirates at admission, once a week thereafter and on discharge. In addition, bacteriological analyses of respiratory tract specimens were conducted to determine patient infectious status.

ResultsThe occurrence of P. aeruginosa respiratory colonization and-or infection was significantly delayed in the probiotic group, with a difference in median delay to acquisition of 11 days versus 50 days P = 0.01, and a nonacquisition expectancy mean of 69 days versus 77 days P = 0.01. The occurrence of ventilator-associated pneumonia due to P. aeruginosa in the patients receiving the probiotic was less frequent, although not significantly reduced, in patients in the probiotic group 2.9% compared with those in the placebo group 7.5%. After multivariate Cox proportional hazards modelling, the absence of probiotic treatment increased the risk for P. aeruginosa colonization in respiratory tract adjusted hazard ratio = 3.2, 95% confidence interval – 1.1 to 9.1.

ConclusionIn this pilot study, oral administration of a probiotic delayed respiratory tract colonization-infection by P. aeruginosa.

Trial registrationThe trial registration number for this study is NCT00604110.

AbbreviationsCFUcolony-forming unit

ICUintensive care unit

Lcr35Lactobacillus casei rhamnosus strain 35

SAPSSimplified Acute Physiology Score

SDDselective decontamination of the digestive tract

VAPventilator-assisted pneumonia

CIconfidence interval

Download fulltext PDF

Author: Christiane Forestier - Dominique Guelon - Valérie Cluytens - Thierry Gillart - Jacques Sirot - Christophe De Champs

Source: https://link.springer.com/

Related documents